Teva Pharmaceuticals considers laying-off 10,000 workers

The Petah Tikva-based company seeks to reduce its expenses by $1.5 billion to $2 billion in the next two years.

By
December 8, 2017 21:09
1 minute read.
Teva Pharmaceuticals considers laying-off 10,000 workers

A building in Jerusalem belonging to generic drug producer Teva. (photo credit: REUTERS/BAZ RATNER)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceuticals, the once soaring yet now battered Israeli drugmaker, is considering layoffs of some 10,000 workers, according to initial reports by Bloomberg. It is unclear how many workers in Israel would be affected.

Last month, the debt-laden company was reportedly considering firing 20% to 25% of its 6,860 workers in Israel. The company was also considering whether to send termination letters to 4,000 people worldwide.

Be the first to know - Join our Facebook page.


The new reported layoff figure is much higher than analysts had previously estimated, and the final number could range between 5,000 and 10,000 jobs lost. A Teva representative declined to comment on the matter. The company employed some 57,000 worldwide as of last year.

The Petah Tikva-based firm seeks to reduce its expenses by $1.5 billion to $2b. in the next two years, Bloomberg reported, with slightly under half of the cuts hitting its research-and-development teams.

In response to the pending layoffs, Teva’s stock leaped to its highest point since October.

CEO Kare Schultz, who took up the post in November, is grappling with heightened competition against Teva’s blockbuster multiple sclerosis drug Copaxone. In addition, US regulations that open up generic drugs to greater competition have led to rapidly falling prices, hitting the company hard.

Teva also faces a heavy debt load of $35b. that followed its ill-advised acquisition of Allergan’s generic unit in 2016. For months now, the company has warned about impending layoffs and further cost-cutting.



The company may also announce the closure of several factories, as well as cutting administrative costs and reducing operational expenses, in response to dismal earnings in 2017. Schultz is promising to publish a detailed plan in mid-December for Teva’s recovery, Bloomberg reports.

Streamlining and layoffs aren’t new to Schultz, who after taking the helm at Danish pharmaceutical company H. Lundbeck A/S, laid off some 17% of the workforce.

In response, the Danish media nicknamed the CEO “hardcore,” according to Reuters.

Related Content

Workers strike outside of the Teva building in Jerusalem, December 2017
December 18, 2017
Workers make explosive threats as massive Teva layoff strikes continue

By MAX SCHINDLER